Biomarkers of Neurodegenerative Disorders
Current Progress and Future Directions
- Publisher's listprice EUR 246.09
-
104 391 Ft (99 420 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 8% (cc. 8 351 Ft off)
- Discounted price 96 040 Ft (91 466 Ft + 5% VAT)
104 391 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Springer
- Date of Publication 7 June 2025
- Number of Volumes 1 pieces, Book
- ISBN 9783031808487
- Binding Hardback
- No. of pages639 pages
- Size 235x155 mm
- Language English
- Illustrations 7 Illustrations, black & white; 32 Illustrations, color 700
Categories
Short description:
This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of the top experts in the field discuss the diagnostic and prognostic value of established and emerging biomarkers in ADRD, their ability to track or monitor disease progression or predict cognitive outcomes, and their potential as novel therapeutic targets. Biomarkers are discussed both in the context of specific disease mechanisms, including amyloid, tau, and synuclein pathologies, endothelial, vascular, neuronal, and synaptic injury, and glial reactivity as well as a wide spectrum of neurodegenerative disorders that encompass various pathologies. Multi-omics approaches in ADRD biomarker and drug target discovery including proteomics, genomics, and transcriptomics are covered. Importantly, the authors highlight the need to integrate biomarkers into various stages of ADRD drug development to accelerate drug discovery and approval. The book provides in-depth insight regarding significant progress in ADRD biomarker research over the last decade, addresses potential challenges in the translation of ADRD biomarkers into the clinic, and proposes important directions for future research.
MoreLong description:
This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of the top experts in the field discuss the diagnostic and prognostic value of established and emerging biomarkers in ADRD, their ability to track or monitor disease progression or predict cognitive outcomes, and their potential as novel therapeutic targets. Biomarkers are discussed both in the context of specific disease mechanisms, including amyloid, tau, and synuclein pathologies, endothelial, vascular, neuronal, and synaptic injury, and glial reactivity as well as a wide spectrum of neurodegenerative disorders that encompass various pathologies. Multi-omics approaches in ADRD biomarker and drug target discovery including proteomics, genomics, and transcriptomics are covered. Importantly, the authors highlight the need to integrate biomarkers into various stages of ADRD drug development to accelerate drug discovery and approval. The book provides in-depth insight regarding significant progress in ADRD biomarker research over the last decade, addresses potential challenges in the translation of ADRD biomarkers into the clinic, and proposes important directions for future research.
MoreTable of Contents:
Section 1: Fluid and Imaging Markers of Pathologies associated with Alzheimer Disease or other Related Dementias.- Chapter 1: Fluid and Imaging Markers of Amyloid Pathology.- Chapter 2: Fluid Markers of Tau Pathology.- Chapter 3: Fluid and Imaging Markers of Synuclein Pathology.- Chapter 4: Fluid and Imaging Markers of Synaptic Injury.- Chapter 5: Fluid Markers of Neuronal and Axonal Injury.- Chapter 6: Fluid and Imaging Markers of Glial Reactivity.- Chapter 7: Fluid and Imaging Markers of Vascular Disease.- Section 2: Fluid and Imaging Markers of Neurodegenerative Disorders.- Chapter 8: Fluid and Imaging Markers of Alzheimer Disease.- Chapter 9: Fluid and Imaging Markers of Frontotemporal Lobar Degeneration.- Chapter 10: Fluid and Imaging Markers of Lewy body dementias.- Chapter 11: Fluid and Imaging Markers of Huntington?s Disease.- Section 3: Single and Integrated Omics Studies in Biomarker Discovery.- Chapter 12: Proteomics for Novel Biomarker and Drug Target Discovery in Alzheimer Disease.- Chapter 13: Genomics and Transcriptomics of Alzheimer Disease.- Section 4: Biomarkers in Clinical and Translational Alzheimer Disease Research.- Chapter 14: Biomarkers in Clinical Trials of Alzheimer Disease: An Overview.- Chapter 15: Biomarkers As Outcome Measures in Clinical Trials of Alzheimer Disease.- Chapter 16: Impact of Pre-analytical Factors on Fluid Biomarker Measurements in Alzheimer Disease.- Chapter 17: Mild Behavioral Impairment and Alzheimer?s Disease Biomarker Sample Enrichment for Clinical Trial Screening and Recruitment.- Section 5: Future Directions in Biomarker Research.- Chapter 18: Extracellular Vesicles as Biomarkers in Alzheimer Disease and Related Dementias.- Chapter 19: Sex Differences in Alzheimer Disease-Related Biomarkers and Dementia Risk.- Chapter 20: Imaging Markers of Amyloid and Tau.- Chapter 21: Novel Markers of Brain Endothelial Injury.- Epilogue: Expert Commentary on Future Directions or Epilogue: Sex/racial differences, standardization, and TDP-43.
More
